<DOC>
	<DOCNO>NCT02147353</DOCNO>
	<brief_summary>External Genital Warts ( EGW ) common sexually transmitted disease associate 30 type Human Papillomavirus ( HPV ) . Cryotherapy effective method EGW treatment . However , multiple session may require report clearance rate range 27-88 % . Sinecatechins 15 % ointment Food Drug Administration approve three time daily application immunocompetent subject 18 year old treatment EGW perianal wart . Treatment EGW cryotherapy follow sinecatechins appear logical . Cryotherapy direct cytodestructive effect immediate short-term efficacy treat EGW , sinecatechins provide field therapy , treat clinical sub-clinical lesion . For study , investigator use sinecatechins 15 % ointment twice daily regimen anticipate synergistic effect cryotherapy provide good efficacy cryotherapy alone . The investigator also anticipate sequential therapy safe .</brief_summary>
	<brief_title>Treatment External Genital Warts With Cryotherapy Sinecatechins 15 % Ointment</brief_title>
	<detailed_description>A total 42 subject receive standardized cryotherapy lesion , use two cycle five second , separate five second interval rest ( Week 0/Baseline ) . One week follow cryotherapy , subject randomize 1:1 either additional treatment sinecatechins 15 % ointment twice daily additional treatment . Those subject randomize additional treatment receive sinecatechins 15 % ointment BID sixteen week , complete clearance EGW , whichever occur first . Additionally , subject advise maintain safe sexual practice recent sexual partner examine EGW . Subjects follow every 8 week total 16 week ( Table 1 ) . EGW lesion count conduct study visit qualify blinded evaluator . Additionally , visit local skin reaction , change concomitant medication , adverse event assess . Any subject receive sinecatechins 15 % ointment discontinue prematurely ask return End Study Visit . Females childbearing potential underwent urine pregnant test visit study treatment period . Subjects meet complete responder criterion , additionally follow assessed Visit5/Week 41 Visit 6/Week 65 assess wart recurrence .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>Adults least 18 year old least two visible EGWs . Subject must good general health confirm medical history . Subject must able read , sign , understand informed consent . Subject must willing forego treatment his/her EGW lesion . Subject willing able participate study outpatient , make frequent visit study center treatment followup period comply study requirement include concomitant medication treatment restriction . If subject female childbearing potential must negative urine pregnancy test result prior study treatment initiation must agree use approve method birth control enrol study . Subject evidence herpes genitalis current and/or recurrent genital uncontrolled infection , include Human Immunodeficiency Virus , Hepatitis B Hepatitis C. Subject unstable medical condition deem clinical investigator . Subject dermatologic disease treatment area may exacerbate treatment propose might impair evaluation EGW lesion . Subject previously treat EGW clinical trial , treatment anogenital wart systemic intake virostatics immunosuppressive medication within 30 day prior Baseline Visit . Women pregnant , lactating , plan become pregnant study period . Subject experience clinically important medical event within 90 day visit ( e.g. , stroke , myocardial infarction , etc ) . Subject active chemical dependency alcoholism assess investigator . Subject known allergy component study ointment . Subject organ allograft , skin condition may interfere study ointment , internal ( vaginal rectal ) warts require treatment . Subject receive follow within 90 day prior study treatment initiation : interferon interferon inducer cytotoxic drug immunomodulators immunosuppressive therapy ( inhaled/ intranasal corticosteroid permit ) oral parenteral corticosteroid topical corticosteroid great 2 gm/day dermatologic procedure surgery study area ( include EGW treatment ) Subject use topical prescription medication study area within 30 day prior study treatment initiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>External Genital Warts</keyword>
	<keyword>Sinecatechins</keyword>
	<keyword>Cryotherapy</keyword>
</DOC>